ORIC-533   Click here for help

GtoPdb Ligand ID: 13294

Synonyms: Example 25 [WO2021087136A1] [1] | ORIC533
Compound class: Synthetic organic
Comment: ORIC-533 is an orally bioavailable CD73 (Ecto-5'-Nucleotidase) inhibitor. Its chemical structure was revealed during the first time disclosures session at the 2024 ACS spring meeting in New Orleans. Multiple myeloma cells in the advanced disease stage have a high adenosine content, and this induces an immunosuppressive effect that shields the malignant cells from innate immune surveillance. CD73 inhibition blocks production of adenosine (from AMP) in multiple myeloma models and reverses the immunosuppressive action of adenosine.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 18
Hydrogen bond donors 7
Rotatable bonds 12
Topological polar surface area 257.18
Molecular weight 605.93
XLogP -2.28
No. Lipinski's rules broken 4

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1CCC(C1)NC2=NC(=NC3=C2C=NN3[C@H]4[C@@H]([C@@H]([C@@H](CO[C@](CO)(COCC5=NNN=N5)P(=O)(O)O)O4)O)O)Cl
Isomeric SMILES OC[C@](COCC1=NNN=N1)(OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N3N=CC4=C(NC5CCCC5)N=C(Cl)N=C34)P(O)(O)=O
InChI InChI=1S/C20H29ClN9O9P/c21-19-24-16(23-10-3-1-2-4-10)11-5-22-30(17(11)25-19)18-15(33)14(32)12(39-18)6-38-20(8-31,40(34,35)36)9-37-7-13-26-28-29-27-13/h5,10,12,14-15,18,31-33H,1-4,6-9H2,(H,23,24,25)(H2,34,35,36)(H,26,27,28,29)/t12-,14-,15-,18-,20+/m1/s1
InChI Key WQAMOSWUARUEOH-GGBXQBQZSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
ORIC Pharmaceuticals are developing ORIC-533 as a drug to treat relapsed/refractory multiple myeloma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05227144 Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma Phase 1 Interventional ORIC Pharmaceuticals 2